Results 161 to 170 of about 2,874 (176)
Some of the next articles are maybe not open access.

ERAP1-ERAP2 haplotypes are associated with ankylosing spondylitis in Polish patients

Human Immunology, 2019
The objective of this case-control study was to evaluate the role of four single-nucleotide polymorphisms in the ERAP1 (rs2287987, rs30187, rs27044) and ERAP2 (rs2248374) genes and their haplotypes in predicting the risk for ankylosing spondylitis (AS) on a well-defined Polish population.
Andrzej, Wiśniewski   +7 more
openaire   +3 more sources

EpCAM associates with endoplasmic reticulum aminopeptidase 2 (ERAP2) in breast cancer cells

Biochemical and Biophysical Research Communications, 2013
Epithelial cell adhesion molecule (EpCAM) is an epithelial and cancer cell "marker" and there is a cumulative and growing evidence of its signaling role. Its importance has been recognized as part of the breast cancer stem cell phenotype, the tumorigenic breast cancer stem cell is EpCAM(+).
Salah-Eldin, Gadalla   +6 more
openaire   +2 more sources

Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum

Nature Immunology, 2005
The generation of many HLA class I peptides entails a final trimming step in the endoplasmic reticulum that, in humans, is accomplished by two 'candidate' aminopeptidases. We show here that one of these, ERAP1, was unable to remove several N-terminal amino acids that were trimmed efficiently by the second enzyme, ERAP2.
Loredana Saveanu   +2 more
exaly   +4 more sources

Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non‐lymphoid human tissues

Journal of Cellular Physiology, 2008
AbstractThe endoplasmic reticulum (ER) aminopeptidases ERAP1 and ERAP2 contribute to generate HLA class I binding peptides. Recently, we have shown that the expression of these enzymes is high and coordinated (with each other and with HLA class I molecules) in immortalized B cells, but variable and imbalanced in human tumour cell lines of various non ...
Fruci D   +7 more
openaire   +4 more sources

Influence of ERAP1 and ERAP2 gene polymorphisms on disease susceptibility in different populations

Human Immunology, 2019
The endoplasmic reticulum aminopeptidases (ERAPs), ERAP1 and ERAP2, makes a role in shaping the HLA class I peptidome by trimming peptides to the optimal size in MHC-class I-mediated antigen presentation and educating the immune system to differentiate between self-derived and foreign antigens.
Yufeng Yao   +3 more
openaire   +2 more sources

Intracellular antigen processing by ERAP2: Molecular mechanism and roles in health and disease

Human Immunology, 2019
Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) is an intracellular enzyme localized in the ER that has been shown to play roles in the generation of peptides that serve as ligands for MHC class I (MHC-1) molecules. Although ERAP2 has been primarily described as an accessory and complementary enzyme to the homologous ERAP1, several lines of evidence ...
José A López, de Castro   +1 more
openaire   +2 more sources

M9.2 Dissecting the allelic architecture of ERAP2: a novel preeclampsia susceptibility gene

Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, 2010
Matthew Johnson1, John Blangero1, Christine East2, Rigmor Austgulen3, Shaun Brennecke2, Eric Moses1. 1Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, TX, USA; 2Department of Perinatal Medicine, Royal Women’s Hospital & Department of Obstetrics & Gynaecology, University of Melbourne, Melbourne, Australia; 3Department ...
Matthew Johnson   +5 more
openaire   +1 more source

Function of ERAP2 (endoplasmic reticulum aminopeptidase 2) in cancer immunity

Journal of Reproductive Immunology, 2021
Nobuki Hayashi   +10 more
openaire   +1 more source

Abstract B080: ERAP2 overexpression and anti-PD-1 resistance in nasopharyngeal carcinoma

Cancer Immunology Research
Abstract Anti-PD1 therapy in nasopharyngeal carcinoma (NPC) demonstrates limited efficacy, with only 19.3% of patients achieving one-year progression-free survival. Identifying predictive biomarkers is crucial for enhancing therapeutic outcomes.
Luvita Suryani   +13 more
openaire   +1 more source

Home - About - Disclaimer - Privacy